“We're in the leading group”
Formycon CEO Dr. Stefan Glombitza spoke with 4investors about the FDA File Acceptance for the pembrolizumab biosimilar candidate FYB206
Dr. Stefan Glombitza in an interview with 4investors
October 16, 2026
Formycon CEO Dr. Stefan Glombitza spoke with 4investors about the FDA File Acceptance for the pembrolizumab biosimilar candidate FYB206
